Patent application of ACPi Anyfusion Pro and ACPi Anyfusion Kit, which are integrated with anticancer drug preparation and infusion

With the cartridge technology, the core source technology of Anyfusion, which rotates the linear motion of a syringe, the application of Anyfusion technology that can integrate anticancer drug preparation and patient injection has been applied for a patent for the ACPi (Anti Cancer Preparation and Infuison) equipment and kit.

Because anticancer drugs are highly toxic, they are mixed (prepared) into a fluid and administered to patients. Because of its strong toxicity, the accuracy of the mixing (preparation) ratio is important. In order to minimize contamination during the preparation process, safety equipment such as protective clothing is provided in a clean room, and then the anticancer agent is extracted from the anticancer medicine bottle with a syringe and introduced into the container to be prepared.

When extracting a drug from an anticancer drug bottle generates negative pressure as much as the extracted amount, so it is difficult to extract the exact amount with a considerable amount of force.If there is a large amount of anticancer drug, it is difficult to extract the drug several times. There is also a risk of puncture and necrosis.

Recently, the extraction process uses a robot of over 1 billion won (installed at Johns Hopkins, Clinic, Samsung Seoul, and Seoul National University Bundang Hospital in the U.S.), or CSTD (Close System Transfer Device) to facilitate extraction by inflow of air as much as the amount extracted during extraction. ) Use an adapter to prepare. Robots are expensive and have a coverage rate of only 25% compared to those manufactured by humans (pharmacists), so we are hesitant to introduce them. CSTD, which is used in about 28 countries, is also used only for facilitating drug extraction, and it is not adopted in Korea because of the expensive adapter cost.

The number of anticancer drugs, TPNs, and important (general) drugs prepared in a clean room in Korea exceeds 3 million per year, with an average fee of 18 million won per year for medical insurance.

As of 2019, the global CSTD market is about 4.4 trillion won and in 2020, COVID19 is expected to be KRW 7.4 trillion, growing by 20-25% every year.

ACPI is ACPi Anyfusion Pro, which applies Anyfusion pump technology, which is a driving device, after installing ACPi Anyfusion Kit, which applies the syringe principle Anyfusion cartridge technology, and can be prepared with a single cartridge before injection into the patient, and Since the set is not disconnected, it is not exposed to the external environment (contamination prevention), so it has an effect of preventing infection, and the price is 1/10 of that of a robot, and it is considered to have high price competitiveness compared to CSTD.

The concept has already been disclosed in many countries, and high needs have been confirmed in some countries and domestic university hospitals.

Semi-automatic can be released within this year, and fully automatic is expected to require a development period of about one year.

We want to preoccupy the market with pre-marketing promotions at international conferences and international exhibitions.

Thank you.